Vanderbilt Clinical Trials

Search All Trials

Volunteer for Research

You could impact how doctors make decisions when treating patients.

Clinical Trials: Diabetes

11 trials found: Print This Page for Your Doctor

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coronary Syndrome Event (IRB No. 110087)

  • Principal Investigator
    Michael E. May
    Medicine, Diabetes, Endocrinology and Metabolism
  • Summary
    The primary objective of this study is to evaluate cardiovascular outcomes with lixisenatide compared to placebo in type 2 diabetic patients who experienced an acute coronary syndrome event, at least 5 days and no more than 12 weeks prior to the screening visit.
  • Contact
    Dianne Davis
    615-Work (615) 936-1140
    Dianne.Davis@vanderbilt.edu

Evaluation of Dermal Myelinated Fibers in Patients with Diabetic Polyneuropathy (IRB No. 100772)

  • Principal Investigator
    Amanda Peltier
    Neurology
  • Summary
    The purpose of the study is to learn more about the nerve damage that happens in diabetes.
  • Contact
    Kay J. Artibee
    615-936-8102
    kay.j.artibee@Vanderbilt.edu

High Fat Diet: Oxidative Effects & Cardiovascular Risk (IRB No. 071325)

  • Principal Investigator
    Heidi J. Silver
    Gastroenterology, Medicine
  • Summary
    The purpose of this study is to evaluate the effects of different types of fat on weight loss and risk factors associated with getting type 2 diabetes and heart disease.
  • Contact
    Taren Spence, RD
    615-936-0985
    taren.spence@vanderbilt.edu

Insulin Detemir in Obesity Management (IDIOM) (IRB No. 101424)

  • Principal Investigator
    Kevin D. Niswender
    Medicine, Diabetes, Endocrinology and Metabolism
  • Summary
    The purpose of this study is to investigate the effect of insulin detemir on body weight, brain function, and other metabolic measures relevant to type 2 diabetes mellitus.
  • Contact
    Wanda Snead
    615-936-1625
    wanda.snead@Vanderbilt.Edu

LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results - A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events (IRB No. 101259)

  • Principal Investigator
    Michael E. May
    Medicine, Diabetes, Endocrinology and Metabolism
  • Summary
    The purpose of this study is to determine the effect of a drug known as liraglutide on heart or blood vessels in people with type 2 diabetes.
  • Contact
    Connie K. Root
    615-343-0132
    connie.root@vanderbilt.edu

Oral Insulin For Prevention of Diabetes In Relatives At Risk For Type 1 Diabetes Mellitus (IRB No. 070030)

  • Principal Investigator
    William E. Russell
    Pediatrics, Pediatric Endocrinology
  • Summary
    This study is designed to see if oral insulin will delay or prevent type one diabetes in blood relatives that have been determined to be at risk.
  • Contact
    Margo M. Black
    615-936-8638 or 888-884-8638
    diabetesresearch@vanderbilt.edu

Pre- & Post-Adaption of AHRQ's Diabetes Summary Guide (IRB No. 101608)

  • Principal Investigator
    Cynthia S. Gadd
    Biomedical Informatics
  • Summary
    We are looking for type 2 diabetes patients and healthcare professionals who care for type 2 diabetes patients to participate in 60-90 minute focus groups for a study to determine the most effective way to communicate information about diabetes treatments. You will be compensated for your participation.
  • Contact
    Xian Ho
    615-343-9346
    xian.ho@Vanderbilt.Edu

Systolic Blood Pressure Intervention Trial (SPRINT) (IRB No. 101157)

  • Principal Investigator
    Julia B. Lewis
    Medicine, Nephrology
  • Summary
    The purpose of this study is to see whether treating blood pressure aggressively will reduce the rate of heart disease and stroke, memory decline or worsening of kidney disease in adults over the age of 55 years, who already have high blood pressure with no history of diabetes or stroke. If you meet study qualifications and wish to take part in the study you will receive the following at no cost:
    • blood pressure medications
    • Physical exams
    • Lab tests
    • Memory tests
    • EKG's (electrocardiograms)
    If you would like to learn more, please contact: Nephrology Clinical Trials Center Julia Lewis or Mohammed Sika 615-936-1179 or 888-537-0497 hypertension
  • Contact
    Mohammed Sika
    615-936-2630
    Mohammed.Sika@vanderbilt.edu

TrialNet Natural History Study of the Development of Type One Diabetes (IRB No. 060684)

  • Principal Investigator
    William E. Russell
    Pediatrics, Pediatric Endocrinology
  • Summary
    The purpose of this study is to learn more about how Type 1 Diabetes occurs. Close blood relatives of someone with diabetes are at greater risk for type 1 diabetes than others. We are screening only close blood relatives of people with type 1 diabetes. This includes brothers, sisters, parents, children, cousins, aunts, uncles, and grandchildren. If you are found to be at high risk for developing type 1 diabetes, you might qualify for research studies that might delay or prevent the onset of type 1 diabetes.
  • Contact
    Margo M. Black
    615-936-8638 or 888-884-8638
    diabetesresearch@vanderbilt.edu

Type 1 diabetes and susceptibility to noise induced hearing loss (IRB No. 091539)

  • Principal Investigator
    Linda J. Hood
    Hearing & Speech
  • Summary
    The purpose of the study is to assess the relationship between diabetes, noise exposure, and hearing loss. We are looking for persons 18-25 years of age with and without type 1 diabetes. The study will consist of a medical history, sound exposure history, and several hearing tests that involve sitting quietly and listening to moderate level sounds. Subjects will be paid for their time.
  • Contact
    Christopher Spankovich
    615-936-6920
    christopher.spankovich@vanderbilt.edu

Type 1 Diabetes TrialNet Protocol TN-09 Effects of CTLA4-Ig (Abatacept) on the Progression of Type 1 Diabetes in New Onset Subjects (IRB No. 080705)

  • Principal Investigator
    William E. Russell
    Pediatrics, Pediatric Endocrinology
  • Summary
    The purpose of this study is to learn if the medication, abatacept, is safe and effective and can help people with newly diagnosed type 1 diabetes by delaying or stopping further destruction of beta cells.
  • Contact
    Anne Brown or Margo Black
    615-936-8638 or 888-884-8638
    diabetesresearch@vanderbilt.edu
Find Us On: